CD47 and gastric cancer: Our results from the flow cytometry analyses and transwell array showed that Bevacizumab significantly decreased the macrophage infiltration compared to controls; however, inhibiting CD47 reversed macrophage infiltration to gastric cancer cells, which was reduced by antiangiogenic therapy.